Incyte | INCY - Stammkapital

Aktienkurs
99.14
Täglich Wechseln
1.40 1.43%
Monatlich
9.75%
Jährlich
58.22%
Q2 Prognose
92.62




Stammkapital Veränderung Datum
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agenus USD 35.32M 2.51M 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amgen USD 539M 1000K 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 946.83M 354.23M 2025-06
Exelixis USD 268.1M 2.03M 2025-09
Gilead Sciences USD 1.24B 1000K 2025-12
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
MacroGenics USD 63.32M 60K 2025-12
Merck USD 2.49B 15.79M 2025-09
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.91B 10.64M 2025-12
Novartis USD 1.91B 10.64M 2025-12
Pfizer USD 5.69B 1000K 2025-09
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Sarepta Therapeutics USD 104.96M 196K 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Vertex Pharmaceuticals USD 254M 0 2025-12